Company Filing History:
Years Active: 2020
Title: Innovations by Lanqing Ma in Cancer Treatment
Introduction
Lanqing Ma is a notable inventor based in Beijing, China. He has made significant contributions to the field of chemical and pharmaceutical technology, particularly in the development of inhibitors for cancer treatment. His work focuses on the STAT3 and ERK signal pathways, which are crucial in cancer cell proliferation and survival.
Latest Patents
Lanqing Ma holds a patent for a "STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof." This invention relates to a chemical and pharmaceutical technology that provides a method for inhibiting the phosphorylation of the transcription factor STAT3 and the phosphorylation of ERK. The inhibitor primarily consists of mogrosides and/or their analogs. The preparation method for these compounds is characterized by its simplicity, strong operability, and high purity of products. This invention has significant implications for the development of drugs aimed at treating tumors, effectively inhibiting cancer cell proliferation and promoting apoptosis.
Career Highlights
Lanqing Ma is affiliated with the Beijing University of Agriculture, where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential impact on cancer therapies, showcasing his commitment to improving health outcomes through scientific advancements.
Collaborations
Lanqing Ma has collaborated with notable colleagues, including Can Liu and Dequan Dou, to further enhance his research efforts and contribute to the scientific community.
Conclusion
Lanqing Ma's innovative work in developing STAT3 and ERK signal pathway inhibitors represents a significant advancement in cancer treatment. His contributions to pharmaceutical technology highlight the importance of research in combating serious health challenges.